Vanguard Global Advisers
BOLT icon

Vanguard Global Advisers’s Bolt Biotherapeutics BOLT Stock Holding History

Vanguard Global Advisers’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24
Closed -$97 – 3656
2026
Q1 		$97 Buy
+24
New +$125 ﹤0.01% 3677

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TC
T3 Companies New York $93.6M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's BOLT Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Bolt Biotherapeutics (BOLT) in Q2 2026, closing a stake of 24 shares — an estimated $97 sold.

Vanguard Global Advisers first reported a position in BOLT in Q1 2026 and held it in 1 quarter. The position peaked at $97 in Q1 2026. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Bolt Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 24 Bolt Biotherapeutics shares in Q2 2026, an estimated $97.
  • Vanguard Global Advisers first reported a position in Bolt Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Bolt Biotherapeutics position peaked at $97 in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.